Summary The aim of this study was to investigate certain genes for their suitability as molecular markers for detection of breast carcinoma cells using the reverse transcriptase-polymerase chain reaction (RT-PCR). RNA was prepared from MCF-7 breast carcinoma cells and peripheral blood leucocytes of healthy female volunteers. This RNA was screened for mRNA of MUC1, cytokeratin 19 (CK19) and CD44 (exons 8-11) by RT-PCR and the results validated by Southern blots. Variable degrees of expression of MUC1 and CD44 (exons 5-11) were detected in normal peripheral blood, rendering these genes non-specific for epithelial cells and therefore unsuitable for use as markers to detect breast carcinoma cells. Although CK1 9 mRNA was apparently specific, it was deemed unsuitable for use as a marker of breast cancer cells in light of its limited sensitivity. Furthermore, an attempt at using nested primers to increase sensitivity resulted in CK19 mRNA being detected after two amplification rounds in blood from healthy volunteers.
Breast cancer is a significant world-wide public health problem. The lifetime risk of a woman developing breast cancer is 1 in 8 and the risk of dying from disseminated disease is 1 in 30 (Feuer et al, 1993) . Despite major advances in adjuvant therapy, improvement in survival has been disappointingly small. Targeting patients appropriately for adjuvant therapy is currently based on clinicopathological prognostic factors. Recent interest has focused on developing laboratory methods to identify disseminated tumour cells in the circulation. This may identify a subgroup of patients suitable for adjuvant systemic therapy.
Several workers have attempted to identify circulating tumour cells in various malignancies (Smith et al, 1991; Burchill et al, 1994; Brown et al, 1995; Burchill et al, 1995; McCulloch et al, 1995; Choy and McCulloch, 1996) . Various techniques, including morphology, flow cytometry and cytogenetics, have been used to detect disseminated tumour cells, but most of these have limited sensitivity and specificity (Frank et al, 1990; Diel et al, 1992; Johnson et al, 1995) and are time-consuming (Gross et al, 1995) . Immunocytochemistry has also been used in an attempt to detect circulating breast carcinoma cells perioperatively, but sensitivity remains a concern with this technique (McCulloch et al, 1995; Choy and McCulloch, 1996) .
Reverse transcriptase-polymerase chain reaction (RT-PCR) is a newer approach to detect circulating tumour cells. Tumour-specific DNA sequence abnormalities have been identified mainly in haematological malignancies, such as acute lymphoblastic leukaemia, for which this technique has been used in the diagnosis and follow-up of patients (Yamada et al, 1990; Steward et al, 1994) . For solid tumours, however, tumour-specific DNA sequence abnormalities are uncommon and, consequently, putative tissue-specific mRNAs have been used as molecular markers to detect circulating tumour cells by RT-PCR (Smith et al, 1991; Burchill et al, 1994; Brown et al, 1995; Eschwege et al, 1995) . The K-ras gene mutation has been used to detect circulating colorectal cancer cells by an immunobead-PCR assay, but this approach is limited because of the low frequency of the gene mutations (30%) in these tumours . No similar specific mutations are known for breast cancer.
We previously reported the detection of tumour cell dissemination by RT-PCR in a pilot study of patients undergoing surgery for breast cancer by using DF3 (MUCI) antigen mRNA as a molecular marker. The aim of the present study was to extend our earlier findings and also examine the role of other epithelial markers.
The three molecular markers studied were MUC1, cytokeratin 19 (CK19) and CD44 (exons 8-11) mRNA. MUCI and CKl9 are thought to be specific and sensitive markers of cells of epithelial origin. The human DF3 breast carcinoma-associated antigen (MUC1) gene encodes a core protein of human polymorphic epithelial mucin (PEM) and is uniformly and highly expressed by malignant human mammary epithelium (Ho et al, 1993) . It is expressed in the tissue of 90% of cases of breast cancer (Papadimitriou et al, 1993) . It has been detected in patients' serum and has been shown to be increased in metastatic disease (Abe and Kufe, 1993) . Cytokeratins are primarily expressed in epithelial cells (Moll et al, 1982) . CK19 has been reported as a specific and sensitive marker for detection of breast carcinoma cells in peripheral blood and bone marrow of patients with breast cancer by RT-PCR (Datta et al, 1994) . CK19 has been shown to be expressed in the tissue of 90% of invasive breast cancer (Papadimitriou et al, 1993) . We also used CD44 (exons 8-11) as a potential marker, as a CD44 mRNA variant encoding these sequences has been shown to be expressed in human colorectal and breast cancer and has been implicated in the induction of the metastatic phenotype in rat pancreatic tumour cells (Gunthert et al, 1991; Hofmann et al, 1991; Delatorre et al, 1995) . CD44 splice variants specific to tumour cells have been described by Matsumura et al (1992) , who reported that peripheral blood leucocytes contained only the standard form of CD44 mRNA, although others have reported traces of these splice variants in blood (Fox et al, 1994) .
MATERIALS AND METHODS
Cell line MCF-7 breast carcinoma cells express MUCI (Abe and Kufe, 1993) and CK19 (Moll et al, 1982) . This cell line was maintained in RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% fetal calf serum. Cells were passaged every 4 days and maintained at 37°C in 5% carbon dioxide.
Blood samples Peripheral blood samples were obtained from healthy female volunteers aged between 18 and 48 years. The first 5 ml was discarded to reduce contamination by epithelial cells at the site of needle entry. A further 10 ml was then collected in potassium ethylenediaminetetraacetic acid (EDTA) bottles and promptly transported to the laboratory at 4°C for immediate processing, as described by Brown et al (1995) .
RNA extraction
In preparation and handling of RNA, scrupulous steps were taken to avoid degradation by contaminating RNAases. Aerosol-resistant, DNAase-and RNAase-free pipette tips were used at all times. Total cellular RNA was extracted from the MCF-7 cell line and normal peripheral blood leucocytes using RNAzol B (Biogenesis, Poole, Dorset, UK) according to the manufacturer's instructions. The concentration of aqueous solutions of RNA was measured spectrophotometrically.
Seeding experiments
To assay the sensitivity of the technique, seeding experiments were carried out by adding varying numbers of MCF-7 cells (0-106 cells) to 10 ml of normal blood. RNA was then extracted as described above.
RT-PCR
Reverse transcription of RNA and PCR amplification of cDNA was carried out using RNA-PCR Kit (GeneAmp RNA-PCR kit, Perkin-Elmer Cetus, Norwalk, CT, USA) after treatment of samples with RNAase-free DNAase I (Dilworth and McCarrey, 1992) . The PCR reaction was carried out in a Perkin-Elmer Cetus 480 DNA thermal cycler; the PCR conditions for each set of primers are given below. A preceding single cycle was the same for all sets of primers and consisted of denaturing cycle at 93°C for 5 min, primer annealing at 55-600C for 5 min and polymerization at 72°C for 15 min.
For MUC 1, the primers used were: CK19 -5' primer 5'-TTANTGGCAGGTCAGGAGAAGAGCC-3'; CK19 -3' primer 5'-AGCTAACCATGCAGAACCTCAACGACCGC-3'.
As described by Datta et al (1994) the 3' primer was designed to preclude transcription of pseudogenes. The PCR conditions were 40 cycles of a single round carried out as described above to yield a 1097-bp PCR product. When two rounds of PCR were performed, nested primers were used as described by Datta et al (1994) .
For CD44, the primers used were:
CD44 ( The PCR conditions were a first round of 20 cycles using primers to exons 4 and 16 of CD44, which produces a fragment of 486 bp from the standard form of CD44 mRNA found in leucocytes (Stamenkovic et al, 1989) in which the variant exons 6-15 have been spliced (Screaton et al, 1992) . These primers also give rise to fragments that include the variant exons 6-14. For the second round of 30 cycles, 1-2 gl of first-round PCR product was used as a template in a 100 gl reaction containing either the exon 8 and 11 primers or exon 12 and 14 primers.
For all samples, the quality of RNA was routinely checked by running the standard form of CD44(S) as an intemal control. 'No RT' controls for all RT-PCR reactions were run as above except that water was substituted for reverse transcriptase. Positive controls were RNA extracted from MCF-7 cell lines, and 'negative controls' contained all components of the RT-PCR reaction but no target RNA template.
Gel electrophoresis of PCR products
RT-PCR products were analysed by 2% agarose gel electrophoresis and visualized through staining with ethidium bromide. A 100-bp DNA ladder or (X174 RF DNA/Hae HI fragments (Gibco, Paisley, UK) were used as size markers.
Southern blot analysis PCR products were transferred from ethidium-stained agarose gels onto a nylon membrane (Hybond N+, Amersham, UK) by ovemight capillary transfer using 0.4 M sodium hydroxide (Sambrook et al, 1989) . Filters were then placed in roller bottles (Becton Dickinson, Oxford, UK) and prehybridized at 65'C for 4-6 h in 20 ml of prehybridization buffer containing 6 x SSC (0.9 M sodium chloride, 0.9 M sodium citrate), 10 x Denhardts (0.2% (w/v) each of Ficol, polyvinylpyrrolidone and bovine serum albumin) and 100 ul ml-denatured sonicated salmon sperm DNA. The prehybridization buffer was then removed and 20 ml of hybridization fluid added containing 1 x 106 c.p.m. ml-Of y_32P_ labelled oligonucleotide probe complementary to an internal sequence in the PCR product for MUCI, and hybridization was continued for a further 12-18 h. (For CK19 and CD44, the downstream primers were used as probes.) Oligonucleotide hybridization temperature was calculated from an empirical formula: T = 4 (G or C) + 2 (A or T) -5°C (Hames and Higgins, 1995). Filters were then washed at T for 60 min in a buffer containing 6 x SSC, 0.1% sodium dodecyl sulphate (SDS) and for 5 min in the same buffer at T + 5°C. At the completion of washing, filters were exposed to radiographic film (Kodak XAR-2 or equivalent) in cassettes with intensifying screen and exposed at -70°C for 12-36 h. 
RESULTS
The seeding experiments demonstrated a decreasing signal from MUC1 mRNA corresponding to a decreasing number of seeded tumour cells, reflecting an apparent sensitivity of one tumour cell per ml of blood. However, the unseeded blood sample in lane 1 showed a faint band, casting doubt on the specificity expression of MUCI mRNA ( Figure IA ). Further samples of normal peripheral blood showed variable expression of MUCI mRNA in four of six volunteers ( Figure 1B) . A further experiment was performed using the standard form of CD44 [CD44(S)] mRNA as internal control. Similar background expression was demonstrated in peripheral blood samples from healthy human volunteers ( Figure IC ). This variation in expression was not due to degradation of RNA in some specimens, as CD44(S) was equally represented in each ( Figure ID ). In total, peripheral blood from 21 of 23 volunteers showed positive bands when assayed for MUCI mRNA. The results of the assay for variants of CD44 in peripheral blood from ten healthy volunteers is depicted in Figure 2 . The metastasis-associated variant (exons 8-11) mRNA is present in four of ten samples.
In contrast, CK19 mRNA was not detected in normal peripheral blood (Figure 3) . However, under the experimental conditions we used, the seeding experiments demonstrated that it was impossible to detect tumour cells at concentrations less than I04 cells per 10 ml of blood, i.e. one tumour cell per 104 white cells (Figure 4 ). This failure of detection did not appear to be due to degradation of RNA, as CD44(S)mRNA was detected in all these samples by RT-PCR ( Figures 3A and 4A) . In order to increase the sensitivity of detection, we attempted to use nested primers as described by Datta et al (1994) , but abandoned this in light of frequency of detection of CK19 mRNA in blood from healthy volunteers.
DISCUSSION
We previously reported the results of a pilot study in which we concluded that DF3 antigen (MUCI) may be used as a specific marker for detecting circulating tumour cells in patients undergoing surgery for breast cancer. Under similar experimental conditions, we have demonstrated background expression of MUCI in the peripheral blood of 21 of 23 healthy human female volunteers. In support of these findings, Hoon et al (1995) Figure 1C MUCI expression in seven of eight normal donor peripheral blood leucocytes and four normal lymph nodes. Our results also raise serious doubts about the value of using CD44 (exons 8-11) mRNA to detect circulating tumour cells because of the frequency with which it is found in normal peripheral blood. It is not known whether the expression of these two markers in normal peripheral blood is due to a small amount of expression of genes in a proportion of peripheral blood cells, or due to the presence of a few epithelial cells in the blood of some individuals.
CK19 mRNA has been claimed to be a specific epithelial cell marker (Datta et al, 1994) . However, the sensitivity of detection of (Chelly et al, 1989 (Hardingham et al, 1993) . It may be applicable in those tumours that carry the mutated gene. Such a specific mutation is as yet unknown in breast cancer. Further work is essential to identify a suitable epithelial marker that has the required specificity and sensitivity to be used reliably in the detection of circulating tumour cells from solid tumours, and meticulous attention to methodology is required to overcome the technical problems with this method before its broader use in clinical practice can be recommended.
